Cargando…
Long-term overall survival from a phase I trial using intratumoral plasmid interleukin-12 with electroporation in patients with melanoma
Autores principales: | Daud, Adil, Takamura, Kathryn Toshimi, Diep, Tu, Heller, Richard, Pierce, Robert H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315267/ http://dx.doi.org/10.1186/1479-5876-13-S1-O3 |
Ejemplares similares
-
Intratumoral electroporation of plasmid interleukin-12: efficacy and biomarker analyses from a phase 2 study in melanoma (OMS-I100)
por: Daud, Adil, et al.
Publicado: (2015) -
Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity
por: Lee, Jack Y., et al.
Publicado: (2022) -
Intratumoral therapies and in-situ vaccination for melanoma
por: Huppert, Laura A., et al.
Publicado: (2022) -
Regulated intratumoral expression of IL-12 as a basis for combination therapy in melanoma
por: Nemunaitis, John J, et al.
Publicado: (2014) -
Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy
por: Mukhopadhyay, Anandaroop, et al.
Publicado: (2018)